American journal of surgery · 2018
Value of ultrasound-guided fine needle aspiration in diagnosing axillary lymph node recurrence after breast cancer surgery.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Vivian Youngjean, Kim Eun-Kyung, Moon Hee Jung, Yoon Jung Hyun, Kim Min Jung
Аннотация
BACKGROUND: This article aims to assess the diagnostic performance of ultrasound-guided fine needle aspiration (US-FNA) in diagnosing axillary lymph node (ALN) recurrence in patients with a history of breast cancer.
METHODS: From January 2005 to June 2015, 231 US-FNA examinations performed for suspicious axillary lesions in 218 patients with a history of breast cancer were included. Diagnostic performance of US-FNA for ALN recurrence were evaluated.
RESULTS: Of the 231 US-FNA examinations, 172 (74.5%) obtained negative and 59 (25.5%) obtained positive cytological results. All US-FNA-negative axillary lesions were considered imaging-cytology concordant and underwent follow-up, with one false-negative result (false negative rate, 1.6% [1/60]). The overall sensitivity, specificity, PPV and NPV of US-FNA for diagnosing ALN recurrence/metastasis per examination were 98.3% (59/60), 100% (171/171), 100% (59/59) and 99.4% (171/172). When excluding nine patients with newly developed contralateral breast cancer, the sensitivity, specificity, PPV and NPV of US-FNA for diagnosing ALN recurrence was 98.1% (51/52),100% (170/170),100% (51/51) and 99.4% (170/171).
CONCLUSIONS: US-FNA is a reliable method for diagnosing axillary recurrence in patients with a history of breast cancer.
METHODS: From January 2005 to June 2015, 231 US-FNA examinations performed for suspicious axillary lesions in 218 patients with a history of breast cancer were included. Diagnostic performance of US-FNA for ALN recurrence were evaluated.
RESULTS: Of the 231 US-FNA examinations, 172 (74.5%) obtained negative and 59 (25.5%) obtained positive cytological results. All US-FNA-negative axillary lesions were considered imaging-cytology concordant and underwent follow-up, with one false-negative result (false negative rate, 1.6% [1/60]). The overall sensitivity, specificity, PPV and NPV of US-FNA for diagnosing ALN recurrence/metastasis per examination were 98.3% (59/60), 100% (171/171), 100% (59/59) and 99.4% (171/172). When excluding nine patients with newly developed contralateral breast cancer, the sensitivity, specificity, PPV and NPV of US-FNA for diagnosing ALN recurrence was 98.1% (51/52),100% (170/170),100% (51/51) and 99.4% (170/171).
CONCLUSIONS: US-FNA is a reliable method for diagnosing axillary recurrence in patients with a history of breast cancer.